|Print Page | Close Window|
Corporate ProfileAbeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.
ABEO $16.20 + 0.05 (0.31%)
October 16, 2017: Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
Data provided by Nasdaq. Minimum 15 minutes delayed.